From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Biomarkers for Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer (NSCLC)

Biomarkers that predict response to therapy are essential, and testing for tumor programmed death ligand 1 (PD-L1) expression is the current standard. In this article, the authors review the biomarker PD-L1 as well as other emerging and investigational tissue-based and serum-based markers that have potential to better predict responders to immunotherapy.

Cancer
Advertisement
News & Literature Highlights
Advertisement
Advertisement